VOLITIONRX LTD 8K

VolitionRx Limited reported second quarter 2026 financial results showing revenue growth for the first half, reduced operating expenses and cash burn, equity financing proceeds, and provided a business update on licensing discussions, collaborations, product development, and reimbursement efforts, with a conference call set for August 14, 2026.

On August 13, 2026, VolitionRx Limited announced its second quarter 2026 financial results and provided a business update, highlighting first-half 2026 revenue of $1.4 million (112% year-over-year growth), second quarter revenue of approximately $0.4 million (flat year-over-year), a 32% reduction in operating expenses versus the prior-year quarter, and a resulting second quarter operating loss of $4.2 million (down 34%), along with lower operating cash burn and equity financing proceeds of $5.3 million. Management also outlined ongoing commercial and clinical initiatives, including active licensing and collaboration discussions with more than a dozen leading diagnostic and liquid biopsy companies, a collaboration with Sysmex Corporation focused on diseases involving Neutrophil Extracellular Traps, progress on a Nu.Q Vet feline lymphoma assay manuscript expected to trigger a $5 million milestone payment upon publication, work on reimbursement submission for Nu.Q Lung Cancer with Hospices Civils de Lyon, and the recent publication of a peer-reviewed paper on its Capture-Seq liquid biopsy technology, and scheduled a conference call for August 14, 2026 to discuss these developments.

Filing Facts

CIK

93314

Ticker

-

Form

8K

Source Type

sec

Accession

0001477932-26-004991

Alert Tier

6